cGMP Recombinant Proteins.
Akron's high-quality cGMP recombinant proteins provide the consistency, safety and efficacy required by today's leading clinical and commercial cell therapy companies.
Cytokines, Chemokines, Growth Factors and more
The result is recombinant proteins with exceptional characterization, purity and consistency from batch to batch. Akron uses robust pharmaceutical grade purification strategies (IEX/SEC/TTF) and always adheres to international standards and guidelines when available. Starting from Albumin to rHu TNF-alpha in cGMP-quality you´ll find these Proteins in the section Essential Extras.
cGMP Cell Culture Tools/ Human Plasma Derived Products
AB-Serum, Albumin and Fibronectin are so available as virus-inactivated and are made to meet the needs of our advanced therapy customers.
Optimal growth and viability within cGMP guidelines
Akron developed each of these products to provide optimal cell growth and viability within cGMP manufacturing guidelines. They take extra care of safety and batch-to-batch consistency. These products are supported by comprehensive manufacturing and pathogen safety documentation designed to meet the requirements of leading health authorities in the US, EU and Asia. You´ll find this in the section Cell Culture Tools.
cGMP Cell Culture Media & Cryo Preservation
Akron offers Cryo-Preservation in cGMP and high-quality research grade. To name one here…
CryoSolutions™ 100% product is cGMP conform.
The formulation contains sterile, filtered DMSO (Dimethyl Sulfoxide, USP/EP), highest purity grade >99.99%. Post-thaw viability is comparable or superior to the leading DMSO-containing cryomedia. Sterility and Bacterial Endotoxin testing are performed per USP/EP on the final product. Media is packaged in glass vials and available in a 100 mL aliquot. Akron’s cGMP-compliant CryoSolutions™ 100% is intended for the cryo-preservation of biological cells in cell culture, stem cells, mammalian cells and biological tissues.
And there's more you might also like to check out... CryoNovo P24
Facts about Akron. References.
Burke CJ, Zylberberg C. Sources of Variability in Manufacturing of Cell Therapies. Regenerative Engineering and Translational Medicine, 2019, DOI 10.1007/s40883-019-00130-5
Harrison RP, Zylberberg E, Ellison S, Levine BL. Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy, 2019, In Press.
El Assal, L. Abou‐Elkacem, A. Tocchio, S. Pasley, S. Matosevic, D. L. Kaplan, C. Zylberberg, U. Demirci. Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy. Adv. Sci.2019, 1802045.
Bruce CJ, Guojun B, Centanni JM, Davis MD, Dobson J, Hare JM, Fields GB, Jove R, Kenyon N, Kahn A, March K, Matosevic S, Mahmood A, Pepine CJ, Ricordi C, Shapiro SA, Zylberberg C, Zylberberg E. Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7(7): 511-512.
National Academies of Sciences, Engineering, and Medicine. 2017. Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies: Proceedings of a Workshop. Washington, DC: The National Academies Press.
Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.
Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Therapy, 2017, 24(8):441-452.
Haddock R, Lin-Gibson S, Lumelsky N, McFarland R, Roy K, Saha K, Zhang J, Zylberberg C. Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century. 2017, National Academy of Medicine, 1-13.
Buckler L, Kunkel E, Thompson M, Ehrhardt R. Technological developments for small-scale downstream processing of cell therapies. 2016, Cytotherapy, 18(3):301-306.
MForesight: Alliance for Manufacturing Foresight. Biomanufacturing Technologies for Regenerative Medicine. 2016.
Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. 2016, Drug delivery, 23(9):3319-3329.
Solomon J, Csontos L, Clarke D, Bonvhadi M, Zylberberg C, McNiece I, Kurtzberg J, Bell R, Deans R. Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. 2016, Cytotherapy, 18(1):1-12.
Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016, 93-94:29-43.
Porat Y, Abraham E, O Karnieli, Nahum S, Woda J, Zylberberg C. Critical elements in the development of cell therapy potency assays for ischemic conditions. 2015, Cytotherapy, 17(7):817-831.
Abbott S, MacKay G, Durdy M, Solomon S, Zylberberg C. Twenty years of the International Society for Cellular Therapies: the past, present and future of cellular therapy clinical development. 2014, Cytotherapy, 16(4):S112-S119.
Assal RE, Guven S, Gurkan UA, et al. Bio-inspired Cryo-ink Preserves Red Blood Cell Phenotype and Function during Nanoliter Vitrification. 2014, Advanced materials, 26(33):5815-5822.